Piramal Pharma
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia i...
Piramal Pharma vs Emcure Pharmaceuticals Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Emcure Pharmaceuticals
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage.
Result Snapshot
Revenue₹2,752 Cr₹2,470 Cr
PAT₹-9 Cr₹244 Cr
EBITDA Margin—19.7%
Sentimentneutralbullish
Key Quotes
We're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.
We crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.